Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23393883 | 1.00 | MEN1 (0.50) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL1763291 | 1.00 | MEN1 (0.50) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL1763293 | 1.00 | MEN1 (0.50) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL13363848 | 1.00 | MEN1 (0.50) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL13436114 | 1.00 | MEN1 (0.50) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL14065400 | 0.90 | MEN1 (0.47) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL4865057 | 0.90 | MEN1 (0.47) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL6924404 | 0.90 | MEN1 (0.47) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL11468464 | 0.87 | MEN1 (0.45) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL19283462 | 0.86 | MEN1 (0.64) | MEN1KMT2APRCPKCNH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4613745-A2 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | Gilead Sciences, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| US-12365666-B2 | Process for preparing a Cot inhibitor compound | GILEAD SCIENCES, INC. (US) | 2025-07-22 | — | — | US | claimed |
| CN-115397824-B | Process for preparing COT inhibitor compounds | 吉利德科学公司 | 2024-10-22 | — | — | CN | claimed |
| US-20240199579-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. | 2024-06-20 | — | — | US | claimed |
| EP-4613745-A2 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | Gilead Sciences, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12365666-B2 | Process for preparing a Cot inhibitor compound | GILEAD SCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4126862-B1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119390681-A | Process for preparing COT inhibitor compounds | 吉利德科学公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-115397824-B | Process for preparing COT inhibitor compounds | 吉利德科学公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240199579-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11845737-B2 | Process for preparing a Cot inhibitor compound | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220380340-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. | 2022-12-01 | — | — | US | disclosed |
| US-20090030216-A1 | ORGANIC SALTS AND METHOD FOR PRODUCING CHIRAL ORGANIC COMPOUNDS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030216-A1 | ORGANIC SALTS AND METHOD FOR PRODUCING CHIRAL ORGANIC COMPOUNDS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20080269529-A1 | Chiral Compound Suitable as a Catalyst for Asymmetric Transfer Hydrogenation | PATHEON HOLDINGS I B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| US-20070276142-A1 | Catalytic Asymmetric Synthesis of Optically Active Alpha-Halo-Carbonyl Compounds | CHEMINOVA A/S (DK) | 2007-11-29 | — | — | US | disclosed |
| US-20070276142-A1 | Catalytic Asymmetric Synthesis of Optically Active Alpha-Halo-Carbonyl Compounds | CHEMINOVA A/S (DK) | 2007-11-29 | — | — | US | disclosed |
| US-20070276142-A1 | Catalytic Asymmetric Synthesis of Optically Active Alpha-Halo-Carbonyl Compounds | CHEMINOVA A/S (DK) | 2007-11-29 | — | — | US | disclosed |
| EP-1716088-A1 | CATALYTIC ASYMMETRIC SYNTHESIS OF OPTICALLY ACTIVE ALPHA-HALO-CAR BONYL COMPOUNDS | Cheminova A/S (DK) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080298-A1 | CATALYTIC ASYMMETRIC SYNTHESIS OF OPTICALLY ACTIVE α-HALO-CARBONYL COMPOUNDS | CHEMINOVA A/S (DK) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845737-B2 | Process for preparing a Cot inhibitor compound | TPO, TFPI, TFPI2 | MEN1 113/4885KMT2A 1577/4885SLC18A3 3530/4885 |
| US-20220380340-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | TPO, TFPI, TFPI2 | MEN1 113/4885KMT2A 1577/4885SLC18A3 3530/4885 |
| US-20070276142-A1 | Catalytic Asymmetric Synthesis of Optically Active Alpha-Halo-Carbonyl Compounds | CBR1, CBR3, HAO1 | MEN1 1649/4885KMT2A 2358/4885SLC18A3 3983/4885 |
| US-20240199579-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | TPO, TFPI, TFPI2 | MEN1 113/4885KMT2A 1577/4885SLC18A3 3530/4885 |
| US-20090030216-A1 | ORGANIC SALTS AND METHOD FOR PRODUCING CHIRAL ORGANIC COMPOUNDS | ICMT, OTC, PNPO | MEN1 2400/4885KMT2A 2501/4885SLC18A3 1574/4885 |
| US-12365666-B2 | Process for preparing a Cot inhibitor compound | TPO, TFPI, TFPI2 | MEN1 113/4885KMT2A 1577/4885SLC18A3 3530/4885 |
| US-20080269529-A1 | Chiral Compound Suitable as a Catalyst for Asymmetric Transfer Hydrogenation | SLC30A6, SLC39A14, SLC30A5 | MEN1 800/4885KMT2A 2438/4885SLC18A3 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.